Pioneering a vascular route to cancer therapy

 

 

Angiex is a biotechnology startup developing an antibody-drug conjugate therapy for cancer against a vascular target, TM4SF1. In addition to its drug development efforts, Angiex provides research services on matters related to its target. For example, Angiex will perform research on the International Space Station in a collaboration with CASIS and Boeing.

 

For more information, visit us at LabCentral or email us at info@angiex.com